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effects on kidney allograft fibrosis in rats that
underwent chronic allograft nephropathy
Lei Luo1, Zhaolin Sun2, Weidong Wu1 and Guangheng Luo2*Abstract
Background: Tacrolimus (FK506) is associated with renal fibrosis in long-term use. Mycophenolatemofetil (MMF)
can also inhibit or attenuate the progression of renal fibrosis. This study aimed to determine the different effects of
FK506 and MMF on fibrosis-associated genes in the kidney in rats that underwent chronic allograft nephropathy
(CAN).
Methods: Fisher (F344) kidneys were orthotopically transplanted into Lewis rat recipients. All recipients were given
Cyclosporin A (CsA) 10 mg/kg-1.d-1 × 10 day and were then randomly divided into three oral treatment groups
(n = 9 in each group): (1) the vehicle group was given vehicle orally; (2) the FK506 group was given 0.15 mg/kg-1.d-1
FK506; and (3) the MMF group was given 20 mg/kg-1.d-1 MMF. At 4, 8, and 12 weeks post-transplantation, serum
creatinine (SCr), collagen deposition, Connective tissue growth factor (CTGF), alpha smooth muscle actin (α-SMA)
and E-cadherin expressions were determined and hematoxylin-eosin (HE) and Periodic acid-Schiff (PAS) stains were
performed.
Results: Renal function progressively deteriorated and showed typical CAN morphology in the vehicle and FK506
groups, while SCr and inflammatory infiltration (Banff score) showed a significant decrease in the MMF group after
8 weeks post-transplantation compared with those in the other groups (p< 0.05). Furthermore, expression levels of
CTGF and α-SMA in the MMF group were significantly reduced, and the down-regulated expression of E-cadherin
was abated (p< 0.05).
Conclusions: MMF showed favorable effects on renal interstitial fibrosis, thus efficiently retarding the progression of
CAN.
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Despite improvements in immunosuppressive protocols,
long-term survival of allografts remains a major impedi-
ment [1]. Research has demonstrated that more than 50 %
of all renal transplants have graft failure, ultimately due to
end-stage renal failure [2]. This process of renal failure was
formerly known as chronic allograft nephropathy (CAN),
which was originally coined as a histological grading of the
extent of interstitial fibrosis (IF) and tubular atrophy (TA)
present in biopsies in 1991. Moreover, other histological* Correspondence: luoguangheng1975@hotmail.com
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reproduction in any medium, provided the orcharacteristics can also be involved in CAN, including
transplant vasculopathy and glomerulopathy [3,4]. A signifi-
cant amount of CAN histological damage can appear from
as early as a median of 3 months post-transplant, and the
condition is progressive [5]. The incremental IF/TA from
immunological and non-immunological causes eventually
leads to chronic graft dysfunction [4].
A number of short- and long-term animal and human
studies on kidney allografts have demonstrated the
nephrotoxicity of tacrolimus [6,7]. Reduced dosing or
withdrawal of tacrolimus, or addition of mycophenolate-
mofetil (MMF) in patients generally results in less
progression in chronic allograft nephropathy (CAN) in-
dices [8]. MMF is the most commonly used drug for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tensity of rejection, MMF may prevent subsequent fibro-
sis and development of CAN [9]. In our previous study,
we observed that FK506 up-regulated the expression of
TGF-β1 and Smad2 in grafts, and down-regulated the
expression of Smad7, while MMF had opposite effects
[10]. Moreover, it has been reported that MMF can
ameliorate transplant fibrosis in an experimental animal
CAN model [10,11].
Connective tissue growth factor (CTGF) is a matricellu-
lar protein, which plays an important role in pathological
fibrosis [12]. Enhanced expression of CTGF is associated
with the process of epithelial-mesenchymal transform-
ation (EMT) within a graft. Moreover, up-regulated ex-
pression of the CTGF gene is closely related to CAN [13].
This study aimed to determine the different effects of
FK506 and MMF on the expression of CTGF and other
fibrosis-associated genes in the kidney in rats that
underwent CAN. We also wished to determine whether
MMF can ameliorate the process of kidney allograft fi-
brosis in an experimental CAN rat model.
Methods
Animals
Male inbred Fischer (F344, RT1lv1) and Lewis (LEW,
RT1l) rats weighing 250 to 300 g were obtained from
Slac Laboratory Animals (Shanghai, China) and were fed
with standard chow and water ad libitum. Fisher rats
were kidney graft donors and Lewis rats were recipients.
Animal experimentation was performed according to the
National Research Council’s criteria (NIH No. 86–23)
and Ethical Committee of the Guizhou Province People’s
Hospital (No. 201102).
Renal transplantation and experimental groups
Male inbred Fischer rat renal grafts were orthotopically
transplanted into Lewis (LEW, RT1l) rats, as described
previously [14]. In brief, the donor was anesthetized by
intraperitoneal injection of urethane (1.0 mL/100 g body
weight). The donor left kidneys were isolated and pre-
served in 0 °C to 4 °C heparin sodium chloride solution
for 1 h to reinforce the cold ischemic injury before trans-
plantation. After left native nephrectomy was performed
in male Lewis recipient males, the donor renal artery were
anastomosed to the aorta of the recipient using inter-
rupted 9–0 nylon sutures. The donor vein was attached to
the inferior vena of the recipient using the cuff technique.
Right native nephrectomy was performed on the 10th
postoperative day. Allograft surgery which meets the fol-
lowing two criteria was considered as valid: (1) When
vascular anastomosis is completed, the transplant kidneys
immediately become red after circulation returns, with a
certain degree of flexibility and hardness. There is no
anastomotic bleeding, the renal artery beats well, andthere is no renal vein distortion and no congestion. There
is visible ureteral peristalsis and urine outflow in the ur-
eteral orifice after 2–3 min. (2) The rats survive for more
than 3 days after transplantation.
All recipient rats received Ciclosporin A (CsA) subcutane-
ously (10 mg/kg-1.d-1×10 d) from day 0 after transplantation
(we used CsA for 10 days after transplantation to prevent the
occurrence of acute rejection, to ensure that the FK506 and
MMF groups were the same at baseline), and were then
divided randomly into three oral treatment groups (each
group, n=9): (1) the vehicle group was given vehicle orally;
(2) the FK506 group was given 0.15 mg/kg-1.d-1 FK506; and
(3) the MMF group was given 20 mg/kg-1.d-1 MMF. The
rats were sacrificed to harvest the renal allografts at 4, 8
and 12 weeks post-transplantation. Only kidneys without
apparent complications of grafting were evaluated. Repre-
sentative portions of the kidneys were snap-frozen in li-
quid nitrogen for nucleic acid and protein purification.
Other samples were fixed in 4 % formalin or 70 % ethanol
for histological evaluation. Blood was collected via direct
heart punctuation for renal function assay.
Renal function and histological evaluation
Serum creatinine (SCr) was measured using an automatic
biochemistry analyzer. Kidneys were fixed in 4 % formalde-
hyde and 70 % ethanol for hematoxylin-eosin (HE) stain
and periodic acid-Schiff (PAS) stain. The PAS reaction was
used to assess the extent of glomerular, tubular and vascular
obliteration. Chronic histological changes were graded from
0 to 3 according to Banff 97 criteria [3] (0, no lesions; 1,
mild lesions; 2, moderate lesions; and 3, severe lesions). All
graft kidney slides were assessed blindly by a pathologist.
Quantitative real time PCR
Total RNA was extracted by using Trizol from tissue
with the Total RNA Isolation kit (Invitrogen, USA).
Total RNA was reverse transcribed using the Prime-
Script RT reagent kit (Takara, Japan) according to the
manufacturer’s instructions. CTGF was quantified by
real-time PCR using SYBR Premix Ex Taq (TaKaRa,
Japan) and the iCycleriQ sequence Detection System
(Bio-Rad, USA). The primers used were as previously
described [15]. The following cycling conditions were
used: 95 °C for 10 min, 95 °C for 30 sec, 60 °C for 1 min,
and 72 °C for 30 sec (40 cycles). The identity of PCR
products was confirmed by sequencing. RT-PCR was
performed in triplicate.
Western blot
Total cell protein was extracted according to the manu-
facturer’s manual (M-PER Mammalian Protein Extrac-
tion Reagent) and transferred to a PVDF membrane.
After blocking with PBS containing 5 % non-fat milk,
the membrane was incubated with CTGF antibody
Figure 1 Renal function and histopathological changes after transplantation. (A) Serum creatinine levels were determined by automatic
biochemistry analyzer 4, 8, and 12 weeks after transplantation. Values are shown as mean± SD from three independent experiments. (B) HE
staining was performed to determine histopathological changes. Original magnification: ×400. (C) The Banff score was scored by the quantitative
criteria of Banff 97 using HE results. Values are shown as mean± SD from three independent experiments. *Significant difference compared with
the control group (p< 0.05).
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with HRP-labeled second antibody. GAPDH was used as
the loading control.Immunohistochemistry
Fibrosis-associated genes, including alpha smooth
muscle actin (α-SMA), E-cadherin, and collagen were
Figure 2 Periodic acid-Schiff (PAS) stain. The PAS reaction was used to assess the extent of glomerular, tubular and vascular obliteration.
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4-μm tissue sections were deparaffinized and antigen
retrieval was performed. The sections were incubated
with primary CTGF antibody (1:100), α-SMA anti-
body (1:100, Denmark), or E-cadherin (1:200 Santa
Cruz, US), followed by incubation with HRP-labeled
second antibody. After washing with PBS, the slides
were then incubated with DAB for 10 min at room
temperature and the results were observed under a
microscope. The images were captured by Nikon
spot cool CCD. The staining results were analyzed
using image-Pro Plus multimedia color pathological
image analysis system.
Masson’s trichrome stain
Deparaffinized tissues sections were stained in Masson
composition solution and light green SF solution. Colla-
gen stains green, blood cells stain orange and muscle
fibers stain red. The staining results were also analyzed
using image-Pro Plus analysis system.Statistical analysis
SPSS11.0 software was used for analysis. The data are
shown as mean± SD. One-way analysis of variance
(ANOVA) was used. Statistical significance was assessed
by using a 2-tailed t-test and defined as p< 0.05.
Results
Renal function and histological evaluation
The rat CAN model, which was reinforced through is-
chemic injury, was successfully achieved. SCr was
assessed at 4, 8 and 12 weeks post-transplantation. All
groups showed a continuous increase in SCr levels.
However, these groups differed slightly from each other.
SCr (mol/L) levels in the vehicle and Fk506 groups were
remarkably increased (p< 0.05) at 8 weeks and 12 weeks
post-transplantation compared with those in the MMF
group (Figure 1A).
Pathological changes of CAN progressively developed in
rat kidney allografts. As shown in Figure. 1B and Figure 2,
at 4 weeks post-transplantation, renal grafts presented
Figure 3 Effect of MMF and FK506 on CTGF expression in renal allografts. (A) Relative mRNA levels were determined by real-time PCR 4, 8,
and 12 weeks after transplantation and normalized to the housekeeping gene GAPDH. Values are shown as mean± SD from three independent
experiments. *Significant difference compared with the control group (p< 0.05). (B) CTGF protein levels were determined by western blot and
GAPDH was used as a housekeeping gene.
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phocytes or mononuclear cell infiltration and without
appearance of acute rejection. At 8 weeks post-
transplantation, grafts showed various combinations of
lesions, including tubular epithelial atrophy, interstitial
fibrosis and arteriosclerosis. At 12 weeks, most of the
tubules were damaged and there was severe interstitial
fibrosis. Pathological lesions in the FK506 and vehicle
groups were more severe than those in the MMF
group. The Banff score in the MMF group was lower
at 4 weeks compared with the vehicle and FK506
groups, but this was not significant (p> 0.05). How-
ever, at 8 weeks and 12 weeks post-transplantation,
the Banff score of the vehicle and Fk506 groups was
significantly higher than that of the MMF group (p
< 0.05, Figure 1 C).
MMF significantly inhibits CTGF expression in renal
allografts
CTGF is a matricellular protein, which plays a crucial
role in renal fibrosis. To determine whether CTGF was
involved in the process of allograft fibrosis, we examined
CTGF mRNA and protein expression levels in the
kidney at 4, 8 and 12 weeks post-transplantation. Mes-
senger RNA levels of CTGF in the MMF group weresignificantly lower at all three time points compared
with those in the vehicle and FK506 groups (p< 0.05,
Figure 3A). Protein expression of CTGF was negative in
normal kidneys (data not shown) and began to be posi-
tively expressed in the vehicle and FK506 groups at
4 weeks post-transplantation. CTGF protein expression
levels of all groups were still up-regulated at 8 weeks
and 12 weeks. MMF treatment resulted in a significant
decrease in CTGF expression compared with that in the
other groups at 4, 8 and 12 weeks post-transplantation
(p< 0.05, Figure 3B).
The expression pattern of α-SMA, collagen and E-cadherin
in renal allografts
Renal tubular epithelial cells (TEC) stimulated with phys-
ical or chemical factors, or induced by cytokines, can be
converted into myofibroblast, which is an important event
in fibrogenesis in renal grafts. Collagen, α-SMA, and E-
cadherin are important molecular markers during the
renal fibrosis process. To analyze the effect of the different
immunosuppressive agents on renal fibrosis, we deter-
mined the expression of α-SMA, collagen deposition and
E-cadherin in renal grafts by immunohistochemistry.
As shown in Figure 4, α-SMA, a molecular marker of
myofibroblasts, was observed in TEC at 8 weeks and
Figure 4 Immunohistochemical staining for α-SMA expression. (B), (E), and (H) show α-SMA expression of renal allografts in the vehicle
group at postoperative days 4, 8, and 12, respectively. (A), (D), and (G) show α-SMA expression of renal allografts in the FK506 group at
postoperative days 4, 8, and 12, respectively. (C), (F), and (I) show α-SMA expression of renal allografts in the MMF group at postoperative days 4,
8, and 12, respectively. Original magnification: ×400.
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sion level of α-SMA in the MMF group was weaker
compared with that in the vehicle and FK506 groups
(p< 0.05) (Table 1).
E-cadherin is a specific molecular marker of epithe-
lium. E-cadherin expression was weaker in TEC in all
groups at 8 weeks post-transplantation (Figure 5). How-
ever, at 12 weeks, atrophied tubules had lost E-cadherin
and only a few of the remaining tubules were positiveTable 1 IOD values of α-SMA in each group 4, 8 and 12w
post-transplantation (×104)
Vehicle FK506 MMF
4w 4.6±0.3 4.8±0.3 4.3±0.4
8w 9.1±0.9 8.5±0.7 6.1±0.4*
12w 19.6±2.4 20.9±1.8 14.2±1.1*
*Significant difference compared with the vehicle group (p<0.05).for E-cadherin. Moreover, E-cadherin expression in the
MMF group was higher than that in the other groups at
4, 8 and 12 weeks post-transplantation (p< 0.05)
(Table 2).
Collagen deposition of renal grafts was detected by
Masson’s trichrome stain. Collagen deposition was
observed in the glomeruli and connective tissues around
blood vessels, and it began to be positively expressed in
the renal tubular basement membrane and kidney inter-
stitium at 4 weeks post-transplantation. It continued to
increase at 8 weeks and 12 weeks post-transplantation in
all groups (Figure 6). Collagen deposition in the MMF
group was significantly weaker compared with that in
the vehicle and FK506 groups (p< 0.05) (Table 3).
Discussion
Like cyclosporine, FK506 is a calcineurin inhibitors
(CNI) and binds to a corresponding protein FK506-
Figure 5 Immunohistochemical staining for E-cadherin expression. (B), (E), and (H) show E-cadherin expression of renal allografts in the
vehicle group at postoperative days 4, 8, and 12, respectively. (A), (D), and (G) show E-cadherin expression of renal allografts in the FK506 group
at postoperative days 4, 8, and 12, respectively. (C), (F), and (I) show E-cadherin expression of renal allografts in the MMF group at postoperative
days 4, 8, and 12, respectively. Original magnification: ×400.
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nophilin complexes inhibit the activity of calcineurin,
which will impede calcium-dependent transduction and
inactivate transcription factors, particularly the NFAT.
NFAT is believed to initiate gene transcription for the
formation of lymphokines such as interleukin-2 and
interferon-c [16]. Thus, FK506 reduce acute rejection
rates and improve patient and allograft survivals by
interfering with T-cell activation. Nevertheless, CNI areTable 2 IOD values of E-cadherin in each group at 4, 8
and 12w post-transplantation (×104)
Vehicle FK506 MMF
4w 18.1±2.2 17.3±2.1 21.6±1.9
8w 7.6±0.6 7.0±0.9 13.5±1.2*
12w 4.2±0.9 4.9±0.6 9.1±1.1*
*Significant difference compared with the vehicle group (p<0.05).toxic, and in particular, they are nephrotoxic. When
strategies of reducing dose or withdrawal of FK506 with
addition of MMF are implemented, there is a trend to-
ward better kidney function [8]. Mycophenolatemofetil
(MMF) is the first pharmaceutical prodrug of mycophe-
nolic acid (MPA) and is used for preventing acute
rejection. MPA inhibits the activity of inosine 5’-
monophosphate dehydrogenase (IMPDH), the rate-
limiting enzyme in the de novo pathway of guanosine
nucleotides synthesis [17–19]. The pharmacological in-
hibition of IMPDH is considered to cause the depletion
of guanosine nucleotides, leading to the suppression of
cell proliferation in activated lymphocytes and a de-
crease of the adhesionmolecules expression [19,20]. This
study aimed to determine its related mechanism through
comparing the effect of FK506 and MMF on CAN as a
single factor after transplantation. And we observed that
MMF could inhibit renal fibrosis in an experimental
Figure 6 Masson’s trichrome stain after transplantation. (B), (E), and (H) show collagen deposition in the vehicle group at postoperative
days 4, 8, and 12, respectively. (A), (D), and (G) show collagen deposition in the FK506 group at postoperative days 4, 8, and 12, respectively. (C),
(F), and (I) show collagen deposition in the MMF group at postoperative days 4, 8, and 12, respectively. Original magnification: ×400.
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of TGF-β1 and Smad2 in grafts [10]. EMT is an import-
ant event in fibrogenesis of renal grafts, in which CTGF
has been used potentially as a biomarker of EMT [11].
In the present study, we evaluated the expression of
CTGF and fibrosis-associated genes in CAN rats treated
with FK-506 or MMF to determine whether there are
differences between these compounds. The pathological
profile demonstrated that CAN lesions were milder in
the MMF group than those in the vehicle and FK506Table 3 IOD values of Collagen deposition in each group
at 4, 8 and 12w post-transplantation (×104)
Vehicle FK506 MMF
4w 6.7±0.5 7.1±0.3 5.2±0.4*
8w 12.1±2.1 12.5±2.6 8.2±0.9*
12w 25.6±2.9 24.2±3.1 11.2±1.1*
*Significant difference compared with the vehicle group (p<0.05).groups, and MMF could effectively prevent fibrosis in
kidney allografts, possibly by reducing the expression of
CTGF, α-SMA and collagen. In addition, although there
was obvious histopathological damage in the MMF
group at 12 week, HE and Masson’s trichrome staining
results showed some parts of glomeruli remain func-
tional. Since Scr levels significantly increased only when
glomerular filtration rate was reduced to 1/3 of normal
levels, it maintains a significant low level in MMF group
compared with other groups at 12 week.
Renal fibrosis correlated with renal TEC lose their polar-
ized phenotype and acquire new characteristic features of
myofibroblasts, the major effector cells responsible for the
excess deposition of interstitial extracellular matrixc
(ECM) under pathological conditions [21]. Alpha-SMA is
a specific molecular marker of activated myofibroblasts,
and a high expression level of α-SMA is associated with
the differentiation from epithelial cells to myofibroblasts
[22,23]. E-cadherin is an adhesive junction protein
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[24]. Under pathological conditions, TEC lose E-cadherin.
The disappearance of E-cadherin in epithelial cells indi-
cates that the cell undergoes an EMT process [25]. Both
α-SMA and E-cadherin are extracellular matrix proteins
correlated with the renal fibrosis process [26,27]. Once
secreted by ECM producing cells, collagen accumulates in
the basement or interstitial space. Disordered synthesis
and secretion and unsatisfactory degradation leads to the
excessive deposition of ECM components and destruction
of tissue architecture. In this study, we evaluated fibrosis-
associated genes to analyze whether FK506 and MMF
modulate the renal fibrosis process in a different manner.
Our results showed that FK506 significantly up-regulated
the expression of α-SMA and collagen, and down-
regulated the expression of E-cadherin in rat kidney grafts.
MMF reduced these effects, suggesting that MMF could
effectively attenuate the fibrosis process in renal allografts
by decreasing the expression of fibrosis-associated genes.
In this study, we also noticed that there was no signifi-
cant difference in the level of CAN and renal fibrosis
between FK506 and vehicle groups. In this study, we
used an enhanced ischemic model which we established
previously, it could successfully accelerate the develop-
ment and progression of CAN in the early stage. We
used CsA to prevent AR after kidney transplantation.
And after that, vehicle group did not use immunosup-
pressive agents and therefore, the rejection may acceler-
ate the development of CAN and renal fibrosis. To some
extent, the use of FK506 could suppress immune rejec-
tion, but its renal toxicity had also accelerated the devel-
opment of CAN and renal fibrosis. Although there was
difference between these two groups in the progression
of CAN and renal fibrosis, however, with no statistical
significant difference. In addition, the combination of
MMF and FK506 is often used in clinical kidney trans-
plantations, further studies are needed to clarify the
combined effects.
CTGF is one of the key cytokines in renal fibrosis, and
it plays an important role in EMT of TEC. Our study
demonstrated that MMF, but not FK506, down-
regulated the expression of CTGF in rat kidney allo-
grafts. A correlation between MMF and EMT might pro-
vide an explanation of the mechanism of action of MMF
to ameliorate transplant fibrosis in experimental models
of CAN. The above results suggested that fibrosis-
associated genes, especially CTGF, are involved in the
compatibility of MMF to ameliorate the process of renal
fibrosis within an experimental model of CAN. Further-
more, our previous results also showed that the change
in CTGF expression was earlier than the pathological
changes (data not shown). Therefore, CTGF has the po-
tential to be a biomarker of CAN, as well as a thera-
peutic target in the management of graft fibrosis [13].Conclusions
In summary, our study confirms that MMF can signifi-
cantly improve graft function and structure, and attenuate
the expression of fibrosis-associated genes. This suggests
that MMF may inhibit the progress of EMT in rat CAN
and block fibrosis in rats undergoing CAN. FK506 can fa-
cilitate the development of renal fibrosis in rat CAN.
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